|
| PD-1抑制剂信迪利单抗治疗肺鳞癌1例分析 |
| Analysis of a Case of Lung Squamous Cell Carcinoma Treated with the PD-1 Inhibitor Sintilimab |
| 投稿时间：2025-09-16 修订日期：2025-11-20 |
| DOI： |
|
 |
| 中文关键词: 肺鳞癌 PD-1抑制剂 信迪利单抗 TCR CDR3多样性 |
| 英文关键词:Squamous cell carcinoma of the lung PD-1 inhibitor Sintilimab TCR CDR3 diversity |
| 基金项目:免疫检查点抑制剂疗效相关且特异性识别肿瘤neoantigen表位的TCR组库建立 |
|
| 摘要点击次数: 19 |
| 全文下载次数: 0 |
| 中文摘要: |
| 本研究旨在探讨PD-1抑制剂信迪利单抗治疗肺鳞癌患者的临床疗效。我们报道了一例76岁男性肺鳞癌患者经信迪利单抗治疗后达到完全缓解的案例。治疗前后，通过肿瘤实体瘤疗效评价标准（RECIST 1.1）和血清肿瘤标志物（角蛋白抗原211、鳞癌细胞抗原）评估疗效，同时监测TCRβCDR3库的变化。结果显示，治疗后患者RECIST 1.1评价标准为完全缓解，肿瘤标志物水平显著下降，且TCRβ CDR3库中出现了与疗效相关的序列变化。结果表明PD-1抑制剂信迪利单抗可有效治疗肺鳞癌。 |
| 英文摘要: |
| This study aims to explore the clinical efficacy of PD-1 inhibitor sintilimab in the treatment of patients with lung squamous cell carcinoma. We report a case of a 76-year-old male patient with lung squamous cell carcinoma who achieved complete remission after sintilimab treatment. Before and after treatment, the therapeutic effect was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and serum tumor markers (cytokeratin antigen 211, squamous cell carcinoma antigen), and the changes in the TCRβ CDR3 repertoire were monitored. The results showed that the patient achieved complete remission according to RECIST 1.1 after treatment, with a significant decrease in tumor marker levels, and sequence changes related to the therapeutic effect appeared in the TCRβ CDR3 repertoire. The results indicate that PD-1 inhibitor sintilimab can effectively treat lung squamous cell carcinoma. |
|
在线阅读
查看/发表评论 下载PDF阅读器 |